162 related articles for article (PubMed ID: 18548092)
21. Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34(+) cells.
Moore S; Haylock DN; Lévesque JP; McDiarmid LA; Samels LM; To LB; Simmons PJ; Hughes TP
Blood; 1998 Oct; 92(7):2461-70. PubMed ID: 9746786
[TBL] [Abstract][Full Text] [Related]
22. Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.
Lu YF; Gavrilescu LC; Betancur M; Lazarides K; Klingemann H; Van Etten RA
Blood; 2012 Jan; 119(1):273-84. PubMed ID: 22072555
[TBL] [Abstract][Full Text] [Related]
23. Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells.
Veena P; Cornetta K; Davidson A; Agüero B; McMahel J; Traycoff CM; Srour EF
Bone Marrow Transplant; 1997 Jun; 19(12):1213-21. PubMed ID: 9208115
[TBL] [Abstract][Full Text] [Related]
24. Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow.
Leemhuis T; Leibowitz D; Cox G; Silver R; Srour EF; Tricot G; Hoffman R
Blood; 1993 Feb; 81(3):801-7. PubMed ID: 7679000
[TBL] [Abstract][Full Text] [Related]
25. Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia.
Greiner J; Schmitt M
Eur J Haematol; 2008 Jun; 80(6):461-8. PubMed ID: 18284627
[TBL] [Abstract][Full Text] [Related]
26. Reconstitution of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation.
Ureshino H; Shindo T; Sano H; Kubota Y; Ando T; Kidoguchi K; Kusaba K; Itamura H; Kojima H; Kusunoki Y; Miyazaki Y; Kojima K; Tanaka H; Saji H; Oshima K; Kimura S
Int J Hematol; 2020 May; 111(5):733-738. PubMed ID: 31873846
[TBL] [Abstract][Full Text] [Related]
27. Differential requirements for myeloid leukemia IFN-γ conditioning determine graft-versus-leukemia resistance and sensitivity.
Matte-Martone C; Liu J; Zhou M; Chikina M; Green DR; Harty JT; Shlomchik WD
J Clin Invest; 2017 Jun; 127(7):2765-2776. PubMed ID: 28604385
[TBL] [Abstract][Full Text] [Related]
28. Graft-versus-leukemia effects of Wilms' tumor 1 protein-specific cytotoxic T lymphocytes in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Wang ZD; Li D; Huang XJ
Chin Med J (Engl); 2010 Apr; 123(7):912-6. PubMed ID: 20497687
[TBL] [Abstract][Full Text] [Related]
29. BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia.
Maguer-Satta V; Petzer AL; Eaves AC; Eaves CJ
Blood; 1996 Sep; 88(5):1796-804. PubMed ID: 8781437
[TBL] [Abstract][Full Text] [Related]
30. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens.
Mutis T; Verdijk R; Schrama E; Esendam B; Brand A; Goulmy E
Blood; 1999 Apr; 93(7):2336-41. PubMed ID: 10090944
[TBL] [Abstract][Full Text] [Related]
31. Antigens in chronic myeloid leukemia: implications for vaccine development.
Smahel M
Cancer Immunol Immunother; 2011 Dec; 60(12):1655-68. PubMed ID: 22033582
[TBL] [Abstract][Full Text] [Related]
32. Peripheral blood is a source of BCR-ABL-negative pre-progenitors in early chronic phase chronic myeloid leukemia.
Lewis ID; Haylock DN; Moore S; To LB; Hughes TP
Leukemia; 1997 Apr; 11(4):581-7. PubMed ID: 9096699
[TBL] [Abstract][Full Text] [Related]
33. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression.
Verfaillie CM; Miller WJ; Boylan K; McGlave PB
Blood; 1992 Feb; 79(4):1003-10. PubMed ID: 1371077
[TBL] [Abstract][Full Text] [Related]
34. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.
Rezvani K; Grube M; Brenchley JM; Sconocchia G; Fujiwara H; Price DA; Gostick E; Yamada K; Melenhorst J; Childs R; Hensel N; Douek DC; Barrett AJ
Blood; 2003 Oct; 102(8):2892-900. PubMed ID: 12829610
[TBL] [Abstract][Full Text] [Related]
35. Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia.
Bornhäuser M; Thiede C; Platzbecker U; Kiani A; Oelschlaegel U; Babatz J; Lehmann D; Hölig K; Radke J; Tuve S; Wermke M; Wehner R; Jähnisch H; Bachmann MP; Rieber EP; Schetelig J; Ehninger G; Schmitz M
Blood; 2011 Jun; 117(26):7174-84. PubMed ID: 21540460
[TBL] [Abstract][Full Text] [Related]
36. Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing.
Matte CC; Cormier J; Anderson BE; Athanasiadis I; Liu J; Emerson SG; Pear W; Shlomchik WD
Blood; 2004 Jun; 103(11):4353-61. PubMed ID: 14982874
[TBL] [Abstract][Full Text] [Related]
37. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
38. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract][Full Text] [Related]
39. Macrophage inflammatory protein-1 alpha receptors are present on cells enriched for CD34 expression from patients with chronic myeloid leukemia.
Chasty RC; Lucas GS; Owen-Lynch PJ; Pierce A; Whetton AD
Blood; 1995 Dec; 86(11):4270-7. PubMed ID: 7492787
[TBL] [Abstract][Full Text] [Related]
40. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
